Oncoheroes Obtains Exclusive Worldwide Oncology Pediatric Rights Of Dovitinib

by Oncoheroes Biosciences

Oncoheroes Biosciences and Novartis have signed a worldwide, exclusive licensing agreement for dovitinib, a multi-tyrosine kinase inhibitor originally developed by Novartis. Under the terms of this ag...

Read more

Oncoheroes Announces Advancement in Pediatric Cancer Research

by Oncoheroes Biosciences

Oncoheroes Biosciences reveals the development of an innovative screening platform aimed at identifying potential drug candidates for medulloblastoma, a type of brain cancer prevalent in children

Read more

FDA Allows Oncoheroes to Begin Two Pediatric Oncology Clinical Trials

by Oncoheroes Biosciences

Oncoheroes Biosciences, Inc. (“Oncoheroes”) announced today that the U.S. Food and Drug Administration (FDA) has allowed the Boston-based biotech to proceed with the investigation of two potential...

Read more

Attending ASEBIO Investors Day, Online

by Oncoheroes Biosciences

Oncoheroes’ CEO, Ricardo Garcia, is attending Asebio Investor Day, a digital event organized by the “Asociación Española de Bioempresas“.

Read more
Subscribe to Directory
Write an Article

Recent News

¿Por qué no es recomendable llevar la ...

La mejor actitud que podemos adoptar es la de trat...

Exposure to Heat and Cold During Pregnan...

The research team observed changes in head circumf...

Using mobile RNAs to improve Nitrogen a...

AtCDF3 gene induced greater production of sugars a...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

New breakthrough in developing more pers...

by Universitat de Barcelona

The results show that adenocarcinoma exhibits much more active and fun...

Photos Stream